CEOs do matter when picking stocks. 5 things we look for in a leader and examples from our portfolio

CEOs do matter when picking stocks. 5 things we look for in a leader and examples from our portfolio


The New York Stock Exchange (NYSE) stands in the Financial District in Manhattan on January 28, 2021 in New York City.

Spencer Platt | Getty Images

It’s not unusual for a company’s stock price to soar — or sink — on news of a CEO shakeup. When Mary Dillon, revered on Wall Street for her eight-year run at Ulta Beauty (ULTA), was named to the top job at Foot Locker (FL) last year, the shoe retailer’s stock jumped 20% in a single session. Dillon’s track record of turning Ulta around is why the Club started a position in Foot Locker back in March. We hope she can work her magic again.

The reaction to Dillon’s appointment highlights a CEO’s outsized influence over a company’s direction — and perception by the market. In fact, up to 45% of a company’s performance is tied to a CEO’s influence, according to estimates from McKinsey & Co. So, CEOs matter when picking stocks — and at the Club, these are the five things we look for when evaluating the leaders of our holdings.



Source

OpenEvidence, the ‘ChatGPT for doctors,’ doubles valuation to  billion
Health

OpenEvidence, the ‘ChatGPT for doctors,’ doubles valuation to $12 billion

A startup widely known as “ChatGPT for doctors” raised a new funding round that values the company at $12 billion. OpenEvidence, based in Miami, Florida, closed a $250 million financing, led by Thrive Capital and DST, the company told CNBC. The startup first raised outside capital in February, when it reeled in $75 million from […]

Read More
Another alliance of health care and AI signals why pharma stocks should be back in favor
Health

Another alliance of health care and AI signals why pharma stocks should be back in favor

Bristol Myers Squibb and Microsoft ‘s new partnership aimed at accelerating early detection of lung cancer marks the latest way health care and artificial intelligence are rapidly intersecting. Bristol Myers said on Tuesday it will work with Microsoft’s AI-powered radiology platform to develop and launch imaging algorithms. These new tools, which can be used to […]

Read More
Drug pricing, patent losses and deals: Here’s what pharma execs see ahead in the industry
Health

Drug pricing, patent losses and deals: Here’s what pharma execs see ahead in the industry

US President Donald Trump arrives for an announcement in the Roosevelt Room of the White House in Washington, DC, US, on Friday, Dec. 19, 2025. Will Oliver | Bloomberg | Getty Images Drug pricing. Looming patent cliffs. Dealmaking. The first year of Trump 2.0. Those are among the themes that dominated conversations last week as drugmakers […]

Read More